Essential Nutrient Found in Eggs Reduces Breast Cancer Risk by 24%

Publication
Article
OncologyONCOLOGY Vol 22 No 5
Volume 22
Issue 5

Choline, an essential nutrient found in foods such as eggs, is associated with a 24% reduced risk of breast cancer, according to a study supported by a grant from the US National Institutes of Health (NIH), to be published in the Federation of American Societies for Experimental Biology (FASEB) Journal's print issue in June.This study adds to the growing body of evidence that links egg consumption to a decreased risk of breast cancer.

Choline, an essential nutrient found in foods such as eggs, is associated with a 24% reduced risk of breast cancer, according to a study supported by a grant from the US National Institutes of Health (NIH), to be published in the Federation of American Societies for Experimental Biology (FASEB) Journal's print issue in June.This study adds to the growing body of evidence that links egg consumption to a decreased risk of breast cancer.

In this new case-control study of more than 3,000 adult women, the risk of developing breast cancer was 24% lower among women with the highest intake of choline compared to women with the lowest intake. Women with the highest intake of choline consumed a daily average of 455 mg of choline or more, getting most of it from coffee, eggs, and skim milk. Women with the lowest intake consumed a daily average of 196 mg or less.

"Choline is needed for the normal functioning of cells, no matter your age or gender," says Steven H. Zeisel, MD, phd, University of North Carolina, who is an author of the study and a leading choline researcher. "Increasing evidence shows that it may be particularly important for women, particularly those of child-bearing age."

Only 10% of Americans currently meet the recommended intake for choline, identifying a need to increase choline intake across the population. According to the Institute of Medicine, adequate choline intake is 550 mg/d for men and breastfeeding women, 425 mg/d for women, and 450 mg/d for pregnant women. One egg contains 125.5 mg of choline, or roughly a quarter the recommended daily supply, making eggs an excellent source of this essential nutrient. Choline is found exclusively in the egg's yolk. Other top food sources of choline include liver, wheat germ, and cauliflower.

Eggs and Decreased Risk of Breast Cancer

Two previously published studies, supported by NIH grants, have shown that women who eat eggs have a lower risk of developing breast cancer:

 

  • A study published in Breast Cancer Research in 2003 by researchers at Harvard University found that eating one egg per day was associated with an 18% reduced risk of breast cancer.

  • A study of Chinese women published in Cancer Epidemiology, Biomarkers & Prevention in 2005 showed that for those who reported eating at least six eggs per week, the risk of developing breast cancer was 44% lower than for those who ate two or fewer eggs per week.

 

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content